Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06830629 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
A Phase 2 study of Proteinuric Kidney Disease, sponsored by Maze Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 20
- Study locations
NCT06830629: Recruiting Phase 2 study of Proteinuric Kidney Disease, sponsored by Maze Therapeutics.
NCT06830629 is a Phase 2 study of Proteinuric Kidney Disease that is actively recruiting participants, run by Maze Therapeutics. The registered enrollment target is 56 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06830629, a Phase 2 study of Proteinuric Kidney Disease, is actively recruiting participants, sponsored by Maze Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Conditions Studied
Interventions
- DRUG MZE829
Study Locations (20)
Florida
- Research Site - Atlantis
- Research Site - Brandon
- Research Site - Brooksville
- Research Site - Hollywood
- Research Site - Melbourne
- Research Site - Miami Lakes
- Research Site - Orlando
Georgia
- Research Site - College Park
- Research Site - Cordele
- Research Site - Macon
- Research Site - Riverdale
- Research Site - Savannah
Alabama
- Research Site - Decatur
- Research Site - Huntsville
- Research Site - Montgomery
California
- Research Site - Granada Hills
Connecticut
- Research Site - Bloomfield
Illinois
- Research Site - Chicago
Kansas
- Research Site - Kansas City
Kentucky
- Research Site - Bowling Green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-02-05 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT06830629 shows while recruiting
NCT06830629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Proteinuric Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which MZE829 is the first listed.
NCT06830629 names 20 study sites across 8 states, led by Florida, Georgia, Alabama.
Frequently Asked Questions
What is clinical trial NCT06830629 about?
NCT06830629 is a clinical study titled "A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease". This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
What is the current status of trial NCT06830629?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2025-02-05. Estimated completion is 2026-09.
What conditions does trial NCT06830629 study?
This clinical trial studies the following conditions: Proteinuric Kidney Disease.
What interventions are being tested in trial NCT06830629?
The interventions under investigation include: MZE829 (DRUG).
Who is sponsoring clinical trial NCT06830629?
This trial is sponsored by Maze Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06830629 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proteinuric Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06830629's enrollment target sits among peer trials
56 1146th of 2000 higher than 848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI